TEMSO phase III results for teriflunomide


REPORT FROM THE 26TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH  IN MS (ECTRIMS), GOTHENBURG, SWEDEN, OCTOBER 13-16, 2010 – The novel oral agent teriflunomide reduces relapse rates by about one-third compared to placebo in patients with relapsing-remitting MS, according to new results from the TEMSO phase III trial presented at ECTRIMS (O’Connor et al. ECTRIMS 2010; abstract 79). The annualized relapse rate (ARR) was significantly reduced in both active treatment arms versus placebo: ARR was 0.370 and 0.369 with teriflunomide 7 mg/day and 14 mg/day, respectively, compared to 0.539 with placebo. The relative risk reductions with teriflunomide were 31.2% and 31.5%, respectively, with the two doses.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page